Editing
Hormonal Therapy
(section)
Jump to navigation
Jump to search
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
=== AUA === * '''2022 AUA Guidelines on Clinically Localized Prostate Cancer''' **'''<span style="color:#ff0000">Palliative ADT monotherapy may be recommended for patients with high-risk prostate cancer, local symptoms, and limited life expectancy.</span>''' *'''2023 AUA Guidelines on Advanced Prostate Cancer''' **'''Metastatic hormone-sensitive prostate cancer''' **'''Metastatic castrate-resistant prostate cancer''' **'''Biochemical recurrence without metastatic disease after exhaustion of local treatment: ADT should not be routinely initiated'''
Summary:
Please note that all contributions to UrologySchool.com may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
UrologySchool.com:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)
Navigation menu
Personal tools
Not logged in
Talk
Contributions
Create account
Log in
Namespaces
Page
Discussion
English
Views
Read
Edit
Edit source
View history
More
Search
Navigation
Main page
Clinical Tools
Guidelines
Chapters
Landmark Studies
Videos
Contribute
For Patients & Families
MediaWiki
Recent changes
Random page
Help about MediaWiki
Tools
What links here
Related changes
Special pages
Page information